Healthcare and Life Sciences

Healthcare and life sciences organisations are navigating unprecedented change.

Pharmaceutical companies face accelerating technological advances, increasing pricing pressures and the ongoing challenge of patent expirations. At the same time, healthcare providers are managing growing complexity through personalised medicines, digital therapies and patients with greater access to both medical information and misinformation.

Oaklin believes the sector is at a major inflection point. Organisations can no longer rely on being "too big to fail".

To remain competitive, organisations across the sector must rethink how they discover, develop and deliver therapies and care. Modernising fragmented operating models is now essential to unlock greater value from data, improve agility and enable collaboration across an increasingly connected and dependent web of networks.

At Oaklin, we help organisations answer the question of how to deliver faster, better, and cheaper, in an increasingly complex and competitive environment.

Our consultants bring deep industry knowledge and cross-sector experience to deliver strategic clarity, operational excellence, and technology-led transformation. Whether you're reimagining patient experience, modernising digital infrastructure, or navigating regulatory change, we work as an extension of your team -grounded in insight, driven by outcomes, and focused on impact.

Recognised by the Financial Times in 2026, Oaklin has a strong track record of guiding pharmaceutical organisations through complex transformations by combining strategic insight with practical delivery expertise.

The Future of Pharma: Oaklin's Perspective

The industry is shifting from traditional, linear operating models toward digitally enabled networks of complex partnerships.

Clinical operations are becoming more data-driven, supply chains more resilience-focused and commercial models more flexible and patient-centric.

To succeed, organisations must rethink:

How innovation is delivered
How data is governed and shared
How partnerships are managed
How technology and workforce strategies evolve together

We help clients design operating models fit for the future of healthcare and life sciences.

How we can help

Operating Model Design and Improvement

We help healthcare and life sciences organisations define operating models that meet their customers' needs and business objectives.

M&A and Alliance Management

We bring together transformation and delivery capability with deep, specialist expertise across all aspects of M&A, divestments and alliances.

Data and AI

We help organisations harness the power of artificial artificial intelligence and data-driven decision making.

Case Studies

Optimising use of data across a FTSE 100 global pharmaceutical company

Oaklin initiated and mobilised a programme of work to improve data access for scientists across early clinical research.

The Oaklin team mapped the current processes and produced an in-depth change assessment and defined the business case. Through Oaklin’s structured approach, we were able to produce prioritised plans for delivery.

Oaklin then successfully mobilised the 2-year programme, allowing the business to maximise the reuse of data and producing a mechanism that could be repeated across other research areas.

Enhancing Customer Experience for Digital Health

Oaklin was engaged to shape, design, develop and manage the transformation of a diagnostics customer journey.

Through close collaboration with our client, Oaklin determined customer experience to be at the core of capturing market share and growth. By applying service design principles and user journey mapping, Oaklin optimized the user experience, keeping laser-focused in maintaining a Trustpilot score of 5 stars.

Oaklin’s open, collaborative and flexible approach allowed us to respond to emerging requirements, in a fast paced, ambiguous and unpredictable environment, with government policy constantly changing.

This work underpinned the delivery of over 4million COVID tests and enabled over 1,500 employees to secure over 50% market share.

SAP Value Optimisation for a Global Pharmaceuticals Manufacturer

Oaklin was engaged to support a global pharmaceuticals manufacturer in identifying unrealised value across their SAP ECC 6.0 EMENA estate. The client experienced inconsistent SAP implementations across EMENA, leading to inefficiencies and integration challenges.

Oaklin helped the organisation to identify value optimisation opportunities from the existing SAP estate by conducting an assessment against SAP standard practice. The assessment focused on a review of what currently works well, gaps between current usage and standard practice, opportunities for improvement and generation of additional value. To support the assessment, Oaklin conducted 64 cross-functional stakeholder interviews across business and IT and reviewed over 200 documents. This enabled a comprehensive RAG assessment across 23 countries within the EMENA estate.

As a result of the assessment, Oaklin proposed 56 prioritised recommendations and defined an indicative roadmap of change. Of the recommendations, 20 were thematic and specific SAP functional recommendations and 36 were wider recommendations which would impact the broader organisation.